|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | TTF-1 positive small cell cancers:Don't think they're always primary pulmonary!显示文摘Thyroid transcription factor 1 (TTF-1) plays a key role in morphogenesis of the lungs and is expressed in up to 90% of pulmonary small cell carcinomas.This explains why this marker is frequently used in the search for the primary origin of metastatic endocrine tumours.Here we report on a TTF-1 expressing mixed endocrine-exocrine carcinoma of the common bile duct in a patient with pulmonary nodules that did not appear to be neoplastic.TTF-1 positivity in pulmonary and extrapulmonary neuroendocrine tumours is reviewed,and we conclude that TTF-1 expression in neuroendocrine tumours of the small-cell type are not uncommon at extrapulmonary locations.Therefore,immunohistochem-istry for TTF-1 in such tumours should be interpreted with caution. | Laurine Verset Marianna Arvanitakis Patricia Loi Jean Closset Myriam Delhaye Myriam Remmelink Pieter Demetter | 2011 | World Journal of Gastrointestinal Oncology2011，3，10： | 2 |
| 2 | Common polymorphism in the PNPLA3 /adiponutrin gene confers higher risk of cirrhosis and liver damage in alcoholic liver disease显示文摘 | Eric Trépo Thierry Gustot Delphine Degré Arnaud Lemmers Laurine Verset Pieter Demetter Romy Ouziel Eric Quertinmont Vincent Vercruysse Leila Amininejad Pierre Deltenre Olivier Le Moine Jacques Devière Denis Franchimont Christophe Moreno | 2011 | Journal of Hepatology2011，，4： | 2 |
| 3 | Epithelial expression of FHL2 is negatively associated with metastasis-free and overall survival in colorectal cancer显示文摘 | Verset L Tommelein J Moles Lopez X | 2013 | Br J Cancer2013，109，： | 1 |
| 4 | Cancer-associated fibroblasts connect metastasis-promoting communication in colorectal cancer 显示文摘 | Tommelein J Verset L Boterberg T | 2015 | Front Oncol2015，5，： | 1 |
| 5 | Clinicopatho-logical significance of indoleamine 2,3-dioxygenase I ex-pression in colorectal cancer显示文摘 | Ferdinande L Decaestecker C Verset L | 2012 | Br J Cancer2012，106，2： | 1 |
| 6 | Marked 25-hydroxyvitamin D deficiency is associated with poor prognosis in patients with alcoholic liver disease<!-- Doctopic: GMD -->显示文摘 | Eric Trépo Romy Ouziel Pierre Pradat Yukihide Momozawa Eric Quertinmont Christine Gervy Thierry Gustot Delphine Degré Vincent Vercruysse Pierre Deltenre Laurine Verset Beatrice Gulbis Denis Franchimont Jacques Devière Arnaud Lemmers Christophe Moreno | 2013 | Journal of Hepatology2013，，2： | 1 |
| 7 | How to prevent complications of liver cirrhosis显示文摘 | Adler M Verset C Moreno G | 2007 | Rev Med Brux2007，28，4： | 1 |
| 8 | Prognostic evaluation of patients with parenehymal cirrhosis: proposal of a new simple score显示文摘 | Adler M Verset D Bouhdid H | 1997 | J Hepatol1997，26，： | 1 |
| 9 | Long-term clinical outcome after endoscopic pancreatic ductal drainage for patients with painful chronic pancreatitis 显示文摘 | Delhaye M Arvanitakis M Verset G | 2004 | Clin Gastroenterol Hepatol2004，2，12： | 1 |
| 10 | Transient elastography using Fibroscan is the most reliable noninvasive method for the diagnosis of advanced fibrosis and cirrhosis in alcoholic liver disease显示文摘 | Michael Fernandez Eric Trépo Delphine Degré Thierry Gustot Laurine Verset Pieter Demetter Jacques Devière Michael Adler Christophe Moreno | 2015 | European Journal of Gastroenterology & Hepatology2015，，： | 1 |
| 11 | Tongue base re- duction with temperature- controlled radiofreguency voiumetric tissue reduction for treatment of obstruc- tive sleep apneasyndrome 显示文摘 | Stuck BA MaurerJT VerseT | 2002 | Aeta Otoiaryngoi2002，122，6： | 1 |
| 12 | Clinicopathological significance of indoleamine 2,3-dioxygenase 1 expression in color- ectal cancer显示文摘 | Ferdinande L Decaestecker C Verset L | 2012 | Br J Cancer2012，106，2： | 1 |
| 13 | Prognostic evaluation of patients with parenchymal cirrhosis:Proposal of a new simple score显示文摘 | Verset D Bouhdid H | 1997 | J Hepatol1997，26，3： | 1 |
| 14 | Molecular chang-es in pancreatic cancer: implications for molecular target- ing therapy显示文摘 | Demetter P Marechal R Verset L | 2012 | A cta Gastroenterol Belg2012，75，2： | 1 |
| 15 | Genetics of alcohol-related hepatocellular carcinoma - its role in risk prediction显示文摘Hepatocellular carcinoma(HCC)is the most common primary liver malignancy,with increasing incidence worldwide.Alcohol-related cirrhosis(AC)accounts for 30%of the global incidence of HCC and HCC-related deaths.With the decline of hepatitis C virus(HCV)and decreasing HCV-related HCC,AC will soon become the leading cause of HCC.Excess alcohol consumption(>80 g per day for>10 years)increases the risk of HCC by 5-fold.However,only up to 35%of excessive drinkers develop cirrhosis and its associated HCC risk.Individual variation in susceptibility to HCC is known,but there is limited information to predict who among the patients is at high risk of progressing to HCC.Clinical risk factors for HCC include male gender,older age,severity of cirrhosis,obesity and presence of type 2 diabetes.In addition to ethnic variability in HCC risk,genetic variants are known to alter the risk of alcohol-related HCC.For example,single nucleotide polymorphisms in PNPLA3(rs738409,C>G)and TM6SF2(rs58542926,C>T)increase the risk of AC-related HCC,whereas HSD17B13(T>A)reduces the risk for HCC.Studies have also confirmed PNPLA3 and TM6SF2 to be independent risk factors for AC-related(but not HCV-related)HCC.Combining genetic risk factors with phenotypic/clinical risk factors has been explored for stratification of patients for HCC development.Risk allele rs378409-G in PNPLA3 when combined with phenotypic/clinical risk factors(BMI,age,sex)has enabled HCC risk stratification of AC patients into low-,intermediate-and high-risk subgroups.Similarly,a combination of the two genetic variants PNPLA3-G and TM6SF2-T has been independently associated with risk of HCC onset.Using a polygenic risk score approach of incorporating several genetic variants,prognostic performance of polygenic risk score that included PNPLA3 rs378409 and TM6SF2 rs58542926 improved HCC prediction better than with either variant alone.Incorporating new variants and risk factors has the potential to build better algorithms/models to predict onset,early diagnosis and treatments for AC-related HCC.However,clinical usefulness of these approaches is yet to be determined. | Ken Liu Gontran Verset Eric Trepo Devanshi Seth | 2020 | Hepatoma Research2020，6，7： | 0 |
| 16 | Real-life multi-center retrospective analysis on nivolumab in difficult-to-treat patients with advanced hepatocellular carcinoma显示文摘BACKGROUND Hepatocellular carcinoma(HCC)is one of the leading causes of cancer-related death worldwide.The landscape of the systemic treatment for advanced HCC is changing quickly,and recently,the standard of care became either atezolizumab plus bevacizumab or tremelimumab plus durvalumab in the single tremelimumab regular interval durvalumab regimen.Nivolumab monotherapy has proven to be effective sometimes for advanced HCC and could be a valuable treatment option for patients outside current treatment indications and reimbursement criteria for the standard of care.This is a particular population of interest.AIM To evaluate the real-world effectiveness of nivolumab monotherapy in patients with advanced HCC who are not eligible for other treatment.METHODS We conducted a retrospective,multicentric study including 29 patients with advanced HCC from 3 Belgian tertiary hospitals.All patients had had prior chemotherapy or were intolerant or ineligible for treatments.All study subjects received nivolumab 3 mg/kg in monotherapy,administered once every two weeks intravenously.Treatment continued until disease progression,severe adverse events or death.Data were retrieved from patients'medical records.The outcome parameters such as radiological response according to response evaluation criteria in solid tumors(RECIST)criteria,the biological response through the evolution of the alpha-fetoprotein(AFP)level,and clinical response considering both the Child–Pugh(CP)score and the World Health Organization(WHO)performance status(PS)were reported.A safety profile was also reported.Statistical analysis was performed using the SPSS Statistics 27 statistical software package.RESULTS The radiological overall response rate(defined as complete or partial response according to the immune RECIST and modified RECIST criteria)to nivolumab monotherapy was 24.1%.The biological overall response rate(defined as a decrease of≥25%in AFP blood level)was 20.7%.Radiological and biological responses were significantly associated both with each other(P<0.001)and with overall survival(P<0.005 for radiological response and P<0.001 for biological response).Overall survival was 14.5 mo(+/-2.1),and progression-free survival was 10.9 mo(+/-2.3).After 4 mo of treatment,78.3%of patients remained clinically stable or even showed improvement in WHO PS.Grade 3 adverse events occurred in 17.2%of patients,none had grade 4 adverse events,and no patients ceased nivolumab due to adverse events.CONCLUSION Nivolumab monotherapy is a good treatment choice in frail patients with HCC who are ineligible for the standard of care or other validated systemic treatments. | Nika De Wilde Luisa Vonghia Sven Francque Thomas De Somer Ali Bagdadi Eva Staub Jasper Lambrechts Ana-Maria Bucalau Gontran Verset Christophe Van Steenkiste | 2022 | World Journal of Hepatology2022，14，8： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员